Assessment of fibrosis progression in untreated Irish women with chronic hepatitis C contracted from immunoglobulin anti-D

被引:40
|
作者
Levine, Robert A.
Sanderson, Schuyler O.
Ploutz-Snyder, Robert
Murray, Frank
Kay, Elaine
Hegarty, John
Nolan, Niamh
Kelleher, Dermot
McDonald, George
O'Keane, J. Conor
Crowe, John
机构
[1] SUNY Upstate Med Ctr, Div Gastroenterol, Dept Med, Syracuse, NY 13210 USA
[2] Mayo Clin, Coll Med, Dept Med, Rochester, MN USA
[3] Mayo Clin, Coll Med, Dept Anat Pathol, Rochester, MN USA
[4] Ctr Outcomes Res & Evaluat, Dept Med, Syracuse, NY USA
[5] Beaumont Hosp, Dept Gastroenterol, Dublin 9, Ireland
[6] Beaumont Hosp, Dept Pathol, Dublin 9, Ireland
[7] St Vincents Univ Hosp, Dept Pathol, Dublin, Ireland
[8] St James Hosp, Dept Hepatol, Dublin 8, Ireland
[9] St James Hosp, Dept Pathol, Dublin 8, Ireland
[10] Mater Misericordiae Univ Hosp, Dept Pathol, Dublin, Ireland
[11] Ctr Liver Dis, Dept Med, Dublin, Ireland
关键词
D O I
10.1016/j.cgh.2006.05.028
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background & Aims: in 1996 we initiated a. retrospective-prospective study in 184 untreated women infected in 1977 with chronic hepatitis C virus (HCV). To provide insight into the natural history of HCV, we determined liver fibrosis outcomes and any predictors of such. Methods: Baseline 1994 biopsy specimens (size, >= 15 mm; portal areas, >= 5) and sequential biopsy specimens were assessed by Ishak score for grade change (increase or decrease of >= 2 points) and stage progression or regression (increase or reduction of >= 1 point), the latter correlated with digital quantification of fibrosis percentage. Results: No baseline biopsy specimens had cirrhosis, therefore all Could potentially progress. Grade and stage scores decreased or increased significantly in 28% and 18% and 24% and 27% of patients, respectively. There was a positive correlation between baseline and sequential grade/stage scores (r = .39, P < .001), and between semiquantitative Ishak scores and fibrosis percentage (Spearman rho = .85; P < .01). Baseline alanine transaminase values (mean, 49 U/L; range, 23-363 U/L) correlated positively with changes in grade (r = .41, P < .01) and stage (r = .39, P < .01), and regression analyses indicated that baseline alanine transaminase value was a good predictor of such changes. Confounding variables (alcohol, smoking, and herbal and paracetamol [acetaminophen] use) did not correlate with histologic outcomes. Conclusions: In a follow-up study, 49% of patients showed no change in fibrosis, 24% showed regression, and only 27% showed progression, including 4 patients (2.1%) who developed stage 6 cirrhosis. Unidirectional sequential grade/stage concordance attested to biopsy sample reliability. Given the current age of these women in their fifth decade, some still may have a risk for more advanced liver disease, but for most of these patients it appears unlikely.
引用
收藏
页码:1271 / 1277
页数:7
相关论文
共 50 条
  • [31] New LncRNAs in Chronic Hepatitis C progression: from fibrosis to hepatocellular carcinoma
    Adriana Camargo Ferrasi
    Geysson Javier Fernandez
    Rejane Maria Tommasini Grotto
    Giovanni Faria Silva
    Joao Goncalves
    Marina C. Costa
    Francisco J. Enguita
    Maria Inês de Moura Campos Pardini
    Scientific Reports, 10
  • [32] Low rate of HCV transmission from women infected with contaminated anti-D immunoglobulin to their family contacts
    Sachithanandan, S
    Fielding, JF
    ITALIAN JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 1997, 29 (01): : 47 - 50
  • [33] RIBA positive, PCR negative Irish anti-D hepatitis C patients have minimal liver inflammation and fibrosis, not predicted by number of positive RIBA bands.
    Kieran, N
    Clarke, G
    Pathmakanthan, S
    MacMathuna, P
    Sullivan, A
    Callagy, G
    OKeane, JC
    Crowe, J
    GASTROENTEROLOGY, 1996, 110 (04) : A1232 - A1232
  • [34] Worsening of steatosis is an independent factor of fibrosis progression in untreated patients with chronic hepatitis C and serial liver biopsies.
    Castera, L
    Hézode, C
    Roudot-Thoraval, F
    Bastie, A
    Zafrani, ES
    Pawlotsky, JM
    Dhumeaux, D
    HEPATOLOGY, 2001, 34 (04) : 224A - 224A
  • [35] Clinical outcomes after hepatitis C infection from contaminated anti-D immune globulin
    Kenny-Walsh, E
    NEW ENGLAND JOURNAL OF MEDICINE, 1999, 340 (16): : 1228 - 1233
  • [36] Clinical outcomes after hepatitis C infection from contaminated anti-D immune globulin
    Lawlor, E
    Columb, G
    NEW ENGLAND JOURNAL OF MEDICINE, 1999, 341 (10): : 762 - 762
  • [37] Non-invasive assessment of fibrosis resolution/progression in chronic hepatitis C patients who received anti-viral therapy
    Shiratori, Y
    Yamada, H
    Ikeda, Y
    Matsumura, M
    Hashimoto, N
    Nakata, R
    Omata, M
    GASTROENTEROLOGY, 2003, 124 (04) : A767 - A767
  • [38] Maternal hepatitis C (HCV) infection and Anti-D immunoglobulin therapy: study testing antibodies, RNA and Genotype of HCV in Baghdad
    Al-Kubaisy, Waqar
    Daud, Suzanna
    Al-Kubaisi, Mustafa Waseem
    Al-Kubaisi, Omar Waseem
    Abdullah, Nik Nairan
    JOURNAL OF MATERNAL-FETAL & NEONATAL MEDICINE, 2019, 32 (20): : 3464 - 3469
  • [39] Impact of pregnancies, oral contraception and menopause on liver fibrosis progression in women with chronic hepatitis C.
    Di Martino, V
    Lebray, P
    Moussalli, J
    Buffet, C
    Poynard, T
    HEPATOLOGY, 2001, 34 (04) : 222A - 222A
  • [40] Hepatitis GBV-C sequences in patients infected with HCV contaminated anti-D immunoglobulin and among iv drug users in Germany
    Schreier, E
    Hohne, M
    Kunkel, U
    Berg, T
    Hopf, U
    JOURNAL OF HEPATOLOGY, 1996, 25 (03) : 385 - 389